Previous 10 | Next 10 |
Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the year with $9.0 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / March 22, 2024 /...
- Company building growing body of preclinical data to guide pathway to first in human trial for DNase-based oncology platform FRAMINGHAM, MA / ACCESSWIRE / January 17, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advan...
Encouraging growing body of preclinical data guiding pathway to first in human trial for DNase-based oncology platform Driving development towards Phase 1 program for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Continuing partnering discus...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Xenetic Biosciences Inc. (XBIO) is expected to report $-1.12 for Q3 2023
Live moderated webcast with Jeffrey Eisenberg, Chief Executive Officer of Xenetic Biosciences on Tuesday, October 24 th at 1:00 PM ET FRAMINGHAM, MA / ACCESSWIRE / October 11, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused ...
FRAMINGHAM, MA / ACCESSWIRE / September 5, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that Jeffrey Eisenberg, Chief Exec...
2023-08-11 10:26:48 ET Xenetic Biosciences press release ( NASDAQ: XBIO ): Net loss for the quarter ended June 30, 2023 was approximately $1.1 million. The Company ended the quarter with approximately $10.7 million of cash and no debt. For further details see: Xe...
- Company continues to execute on plan to advance DNase-based oncology program towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors FRAMINGHAM, MA / ACCESSWIRE / August 11, 2023 / Xenetic Biosciences, Inc. (NAS...
Live moderated video webcast on Wednesday, July 12 th at 10:00 AM ET FRAMINGHAM, MA / ACCESSWIRE / July 5, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard ...
News, Short Squeeze, Breakout and More Instantly...
Xenetic Biosciences Inc. Company Name:
XBIO Stock Symbol:
NASDAQ Market:
Xenetic Biosciences Inc. Website:
Ongoing preclinical studies with multiple data readouts expected throughout remainder of 2024 Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the qu...
Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the year with $9.0 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / March 22, 2024 /...
- Company building growing body of preclinical data to guide pathway to first in human trial for DNase-based oncology platform FRAMINGHAM, MA / ACCESSWIRE / January 17, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advan...